The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: A preliminary investigation of tolerability

Journal of Psychopharmacology

Volumn 25, Issue 11, 2011, Pages 1562-1567

  Carhart Harris, Robin L ^a,b   Williams, Tim M ^b   Sessa, Ben ^b   Tyacke, Robin J ^a,b   Rich, Ann S ^b   Feilding, Amanda ^c   Nutt, David J ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c THE BECKLEY FOUNDATION   (United Kingdom)

Author keywords

hallucinogen; psilocybin; psychedelic

Indexed keywords

PSILOCYBINE;

ADULT; ARTICLE; BLOOD PRESSURE; BRAIN BLOOD FLOW; BRAIN FUNCTION; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEART RATE; HEAT SENSATION; HUMAN; HUMAN EXPERIMENT; MALE; NEUROIMAGING; NORMAL HUMAN; PERCEPTION DISORDER; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VISUAL DISORDER;

ADULT; CEREBROVASCULAR CIRCULATION; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HALLUCINOGENS; HUMANS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PILOT PROJECTS; PSILOCYBINE;

EID: 83455162345     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881110367445     Document Type: Article

References (15)

1. Dittrich A. The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry. 1998 ; 31 (Suppl. 2). 80-84 (Pubitemid 28396276)
2. Gouzoulis-Mayfrank E, Schreckenberger M, Sabri O, et al. Neurometabolic effects of psilocybin, 3,4-methylenedioxyethylamphetamine (MDE) and d-methamphetamine in healthy volunteers. A double-blind, placebo-controlled PET study with [18F] FDG. Neuropsychopharmacology. 1999 ; 20: 565-581
3. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006 ; 187: 268-283 (Pubitemid 44088380)
4. Grinspoon L, Bakalar JB Psychedelic drugs reconsidered. New York: Basic Books ; 1979 :
5. Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX. Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv. 1997 ; 72: 175-184 (Pubitemid 27246716)
6. Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a doubleblind, placebo-controlled dose-effect study. Psychopharmacology (Berl). 2004 ; 172: 145-156 (Pubitemid 38388763)
7. Hofmann A, Frey A, Ott H, Petr-Zilker T, Troxler F. Elucidation of the structure and the synthesis of psilocybin. Experientia. 1958 ; 14: 397-399
8. Hofmann A, Heim R, Barck A, et al. Psilocybin and psilocin. Helv Chim Acta. 1959 ; 42: 1557-1572
9. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008 ; 22: 603-620
10. Lee AA, Shlain B Acid dreams. The complete social history of LSD. New York: Grove Press ; 1985 :
11. Leuner H Hallucinogenic drugs and their psychotherapeutic use. Crockett R Sandison R Walk A, ed. London: H.K.Lewis ; 1963: 67-73.
12. Nichols DE. Hallucinogens. Pharmacol Ther. 2004 ; 101: 131-181 (Pubitemid 38167565)
13. Osmond H. A review of the clinical effects of psychotomimetic Agents. Ann N Y Acad Sci. 1957 ; 66: 418-434
14. Spencer AM. Lysergic acid diethylamide. Br Med J. 1966 ; 2: 49-49
15. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997 ; 16: 357-372 (Pubitemid 27211734)